Entos Pharmaceuticals has announced an investment of C$62m ($43.05m) from the government of Canada, further leveraging C$15.5m previously announced by the Alberta government.
The combined C$77.5m will be directed towards a C$198.5m project aimed at establishing a 103,000 ft² research and development (R&D) centre and good manufacturing practice (GMP) biomanufacturing facility in Edmonton, Alberta.
The facility will develop and manufacture the Entos Fusogenix PLV [proteolipid vehicle] drug delivery platform, along with medicines.
Built upon Entos’ collaboration with Eli Lilly & Company, the project will support the development of nucleic acid products for the central and peripheral nervous system.
It will also advance collaborations with OncoSenX, Aegis Life and Oisin Biotechnologies, furthering treatments for cancer and rare genetic disorders such as Stargardt Disease, Duchenne muscular dystrophy and congenital lipodystrophy.
Designed as a hub for next-generation therapeutics, the centre will encourage co-operative efforts between Entos, Canadian academic institutions and industry partners.
These collaborations are set to boost expertise within the country’s life sciences sector and attract international investment, talent and collaborations.
Entos Pharmaceuticals CEO John Lewis stated: “We are thrilled to receive this investment, which will enable us to build a cutting-edge GMP biomanufacturing facility and innovative R&D centre in Edmonton, Alberta, Canada.
“It will help us develop, scale up, produce and commercialise Fusogenix PLV therapeutics to address critical health needs and fill gaps in Canada’s domestic manufacturing capacity.”
Entos originated from the University of Alberta’s Faculty of Medicine and Dentistry.
Headquartered in Canada, the company operates through its wholly owned subsidiaries in London, UK and San Diego, California.
Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
